Hepatitis C News and Research

Latest Hepatitis C News and Research

Gilead enters agreement for Pharmasset acquisition

Gilead Sciences, Inc. and Pharmasset, Inc. announced today that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.

21 Nov 2011

Research roundup: The effect of heart drug costs; Doctors' financial incentives when ordering stress tests

The researchers examined whether drug costs for heart attack patients affects health. Half of a group of more than 5,000 patients were given prescription coverage that eliminated co-payments and expanded drug choices. The others had "usual prescription coverage."

18 Nov 2011

Inovio announces results from SynCon avian influenza vaccine Phase I study

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.

18 Nov 2011

Annual report on sexually transmitted infections reveals rising trends

New figures reveal that cases of some common sexually spread diseases continue to increase in the United States. These numbers come in the annual report on sexually transmitted disease released by health officials this Thursday.

17 Nov 2011

LGBT seniors face higher rates of disability, physical and mental distress

Aging and health issues facing lesbian, gay, bisexual and transgender baby boomers have been largely ignored by services, policies and research. These seniors face higher rates of disability, physical and mental distress and a lack of access to services, according to the first study on aging and health in these communities.

17 Nov 2011

EPO-secreting engineered vessels could reverse anemia

Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into the bloodstream.

15 Nov 2011

Sinovac third quarter sales increase 60.8% to $15.4 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011.

14 Nov 2011

Senior UK Parliamentarians visit Bangladesh to see full impact of pneumonia on children

To mark World Pneumonia Day, a senior UK parliamentary delegation travelled to Dhaka this week to see firsthand the full impact of pneumonia on Bangladeshi children.

14 Nov 2011

China Pharma third quarter revenue increases 12% to $21.0 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended September 30, 2011.

11 Nov 2011

N-acetylcysteine plus cortisone shows promise against acute alcoholic hepatitis

Acute alcoholic hepatitis is one of the most serious forms of alcoholic liver disease, affecting individuals with chronic excessive alcohol consumption, which generally equates to more than 50 grams of alcohol per day, over a period of more than three to six months. The disease is characterized by liver failure and acute jaundice (icterus), which may induce a coma through liver failure and an ensuing death rate of between 40-45% within the first six months.

11 Nov 2011

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

GenMark Diagnostics, Inc. today reported financial results for the third quarter ended September 30, 2011.

10 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Safe disposal of needles, syringes and other sharps

Many people use needles, syringes and lancets—called "sharps"—to manage their medical conditions at home. These conditions include diabetes, allergies, infertility, arthritis, hepatitis, HIV, blood clotting disorders, migraines and cancer.

9 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

MBL-HCV1 can reduce viral load in liver transplant patients

A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus for at least a week after transplant and delayed the time to viral rebound.

8 Nov 2011

Economic burden of chronic hepatitis C-related liver disease

Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

8 Nov 2011

Beware mail order Chicken pox warn Doctors

Doctors have warned against a new trend that has emerged via social networking websites like Facebook - one that guides parents through a process of exposing their children to chicken pox, so that they can get the virus, early and avoid any need for vaccination.

7 Nov 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.

7 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011